MindImmune Receives ADDF Backing to Support First-in-Human Trials
RightHill Ventures portfolio company MindImmune has received $5m in backing from the Alzheimer’s Drug Discovery Foundation (ADDF), supporting the company’s advancement into their first-in-human trials.
This most recent A3 close from ADDF builds on the November 2025 close of $10.2m which included RightHill Ventures along with Slater Technology Fund, Dolby Family Ventures, Gates Frontier, Pfizer Ventures, and Foundation for a Better World.
MindImmune is developing therapeutics aimed at immune-driven mechanisms in the brain, an area that continues to gain importance in the treatment of Alzheimer’s and related disorders. Support from ADDF adds meaningful momentum as the company moves its program into the clinic.
This latest funding marks an important step in MindImmune’s development and reinforces the scale of the opportunity the company is pursuing.